06
2021-09
Kintor Pharma Included in Hong Kong Stock Connect Program
Suzhou, September 6, 2021 — 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company’s stock has been included in the Hong Kong Stock Connect program (the “Hong Kong Stock Connect”), effective September 6, 2021.
27
2021-08
Kintor Pharma Announces 2021 Interim Results
Suzhou, August 27, 2021 — 真人直营投注网站 ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.
25
2021-08
Suzhou, August 25 2021-- 真人直营投注网站 (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has entered into a licensing agreement with PT Etana Biotechnologies Indonesia, on the commercialization of proxalutamide for the treatment of COVID-19 in Indonesia.
20
2021-08
Inclusion of Kintor as a Constituent Stock of HSCI
Suzhou, August 20, 2021 — 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company’s stock has been included in the Hang Seng Composite Index, effective September 6, 2021.
28
2021-07
Suzhou, July 28, 2021 — 真人直营投注网站 (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
16
2021-07
Suzhou, July 16, 2021 - 真人直营投注网站 (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn